215 related articles for article (PubMed ID: 23859623)
1. New fluorescent substrate enables quantitative and high-throughput examination of vesicular monoamine transporter 2 (VMAT2).
Hu G; Henke A; Karpowicz RJ; Sonders MS; Farrimond F; Edwards R; Sulzer D; Sames D
ACS Chem Biol; 2013 Sep; 8(9):1947-54. PubMed ID: 23859623
[TBL] [Abstract][Full Text] [Related]
2. Assessing Vesicular Monoamine Transport and Toxicity Using Fluorescent False Neurotransmitters.
Black CA; Bucher ML; Bradner JM; Jonas L; Igarza K; Miller GW
Chem Res Toxicol; 2021 May; 34(5):1256-1264. PubMed ID: 33378168
[TBL] [Abstract][Full Text] [Related]
3. A fluorescent-based assay for live cell, spatially resolved assessment of vesicular monoamine transporter 2-mediated neurotransmitter transport.
Bernstein AI; Stout KA; Miller GW
J Neurosci Methods; 2012 Aug; 209(2):357-66. PubMed ID: 22698664
[TBL] [Abstract][Full Text] [Related]
4. High-throughput screening system for dynamic monitoring of exocytotic vesicle trafficking in mast cells.
Kiyoi T; Liu S; Sahid MNA; Shudou M; Maeyama K; Mogi M
PLoS One; 2018; 13(6):e0198785. PubMed ID: 29883480
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and Discovery of Arylpiperidinylquinazolines: New Inhibitors of the Vesicular Monoamine Transporter.
Provencher BA; Eshleman AJ; Johnson RA; Shi X; Kryatova O; Nelson J; Tian J; Gonzalez M; Meltzer PC; Janowsky A
J Med Chem; 2018 Oct; 61(20):9121-9131. PubMed ID: 30240563
[TBL] [Abstract][Full Text] [Related]
6. Identification of the substrate binding region of vesicular monoamine transporter-2 (VMAT-2) using iodoaminoflisopolol as a novel photoprobe.
Gopalakrishnan A; Sievert M; Ruoho AE
Mol Pharmacol; 2007 Dec; 72(6):1567-75. PubMed ID: 17766642
[TBL] [Abstract][Full Text] [Related]
7. Immunochemical localization of vesicular monoamine transporter 2 (VMAT2) in mouse brain.
Cliburn RA; Dunn AR; Stout KA; Hoffman CA; Lohr KM; Bernstein AI; Winokur EJ; Burkett J; Schmitz Y; Caudle WM; Miller GW
J Chem Neuroanat; 2017 Oct; 83-84():82-90. PubMed ID: 27836486
[TBL] [Abstract][Full Text] [Related]
8. The molecular chaperone Hsc70 interacts with the vesicular monoamine transporter-2.
Requena DF; Parra LA; Baust TB; Quiroz M; Leak RK; Garcia-Olivares J; Torres GE
J Neurochem; 2009 Jul; 110(2):581-94. PubMed ID: 19457116
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of neurotransmitter transport and drug inhibition in human VMAT2.
Pidathala S; Liao S; Dai Y; Li X; Long C; Chang CL; Zhang Z; Lee CH
Nature; 2023 Nov; 623(7989):1086-1092. PubMed ID: 37914936
[TBL] [Abstract][Full Text] [Related]
10. The psychostimulant (±)-cis-4,4'-dimethylaminorex (4,4'-DMAR) interacts with human plasmalemmal and vesicular monoamine transporters.
Maier J; Mayer FP; Luethi D; Holy M; Jäntsch K; Reither H; Hirtler L; Hoener MC; Liechti ME; Pifl C; Brandt SD; Sitte HH
Neuropharmacology; 2018 Aug; 138():282-291. PubMed ID: 29908239
[TBL] [Abstract][Full Text] [Related]
11. The expression of vesicular glutamate transporter 3 and vesicular monoamine transporter 2 induced by brain-derived neurotrophic factor in dorsal root ganglion neurons in vitro.
Liu D; Bi Y; Liu Z; Liu H; Li Z
Brain Res Bull; 2014 Jan; 100():93-106. PubMed ID: 24316448
[TBL] [Abstract][Full Text] [Related]
12. Lobelane inhibits methamphetamine-evoked dopamine release via inhibition of the vesicular monoamine transporter-2.
Nickell JR; Krishnamurthy S; Norrholm S; Deaciuc G; Siripurapu KB; Zheng G; Crooks PA; Dwoskin LP
J Pharmacol Exp Ther; 2010 Feb; 332(2):612-21. PubMed ID: 19855096
[TBL] [Abstract][Full Text] [Related]
13. Mitochondrial complex I inhibitor rotenone inhibits and redistributes vesicular monoamine transporter 2 via nitration in human dopaminergic SH-SY5Y cells.
Watabe M; Nakaki T
Mol Pharmacol; 2008 Oct; 74(4):933-40. PubMed ID: 18599602
[TBL] [Abstract][Full Text] [Related]
14. Normal biogenesis and cycling of empty synaptic vesicles in dopamine neurons of vesicular monoamine transporter 2 knockout mice.
Croft BG; Fortin GD; Corera AT; Edwards RH; Beaudet A; Trudeau LE; Fon EA
Mol Biol Cell; 2005 Jan; 16(1):306-15. PubMed ID: 15496457
[TBL] [Abstract][Full Text] [Related]
15. GZ-11608, a Vesicular Monoamine Transporter-2 Inhibitor, Decreases the Neurochemical and Behavioral Effects of Methamphetamine.
Lee NR; Zheng G; Leggas M; Janganati V; Nickell JR; Crooks PA; Bardo MT; Dwoskin LP
J Pharmacol Exp Ther; 2019 Nov; 371(2):526-543. PubMed ID: 31413138
[TBL] [Abstract][Full Text] [Related]
16. Phenyl ring-substituted lobelane analogs: inhibition of [³H]dopamine uptake at the vesicular monoamine transporter-2.
Nickell JR; Zheng G; Deaciuc AG; Crooks PA; Dwoskin LP
J Pharmacol Exp Ther; 2011 Mar; 336(3):724-33. PubMed ID: 20876747
[TBL] [Abstract][Full Text] [Related]
17. Transport and inhibition mechanisms of human VMAT2.
Wu D; Chen Q; Yu Z; Huang B; Zhao J; Wang Y; Su J; Zhou F; Yan R; Li N; Zhao Y; Jiang D
Nature; 2024 Feb; 626(7998):427-434. PubMed ID: 38081299
[TBL] [Abstract][Full Text] [Related]
18. Identification of conformationally sensitive residues essential for inhibition of vesicular monoamine transport by the noncompetitive inhibitor tetrabenazine.
Ugolev Y; Segal T; Yaffe D; Gros Y; Schuldiner S
J Biol Chem; 2013 Nov; 288(45):32160-32171. PubMed ID: 24062308
[TBL] [Abstract][Full Text] [Related]
19. The vesicular monoamine transporter 2: an underexplored pharmacological target.
Bernstein AI; Stout KA; Miller GW
Neurochem Int; 2014 Jul; 73():89-97. PubMed ID: 24398404
[TBL] [Abstract][Full Text] [Related]
20. Vesicular monoamine transporter, type 2 (VMAT2) expression as it compares to insulin and pancreatic polypeptide in the head, body and tail of the human pancreas.
Freeby M; Ichise M; Harris PE
Islets; 2012; 4(6):393-7. PubMed ID: 23221614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
